Biotech sector performance: Overall investor sentiment toward biotechnology companies affects TCBIO's stock. A strong biotech sector lifts TCBIO, while weakness hurts it.

Clinical trial results: Positive data from TCBIO's clinical trials for its drug candidates drives up the stock. Negative or inconclusive results cause it to fall.

Regulatory approvals: FDA approval of TCBIO's drugs leads to significant stock price increases. Rejections or delays have the opposite effect.

Competition: Advances or setbacks from TCBIO's competitors in similar therapeutic areas influence investor perception and the stock price.

Partnerships and collaborations: Strategic alliances with larger pharmaceutical companies or research institutions boost confidence and the stock price.

Financial performance: TCBIO's cash reserves, burn rate, and ability to secure funding impact investor sentiment. A strong balance sheet supports the stock.

Management team: The experience and reputation of TCBIO's management team affect investor confidence. Key personnel changes can influence the stock price.

Market conditions: Broader economic trends and overall market sentiment impact all stocks, including TCBIO. A bull market helps, while a bear market hurts.

News and events: Company-specific news, industry conferences, and scientific publications related to TCBIO can all move the stock price.

Investor sentiment: The overall mood of investors toward TCBIO, driven by media coverage and social media buzz, can create buying or selling pressure.